ClinicalTrials.gg
RecruitingNCT07149649Updated Oct 28, 2026

Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

A Phase 2/3 interventional study of Magnesiocard and Magnesium Diasporal in Metastatic NSCLC - Non-Small Cell Lung Cancer, sponsored by Swiss Cancer Institute. Recruiting at 9 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Swiss Cancer Institute · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 28, 2026Start date moved1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 186 studies in Carcinoma, Non-Small-Cell Lung with a site in Switzerland — 42 open to participants now, 67 under way, 33 of them phase 3. Carcinoma, Non-Small-Cell Lung · Switzerland.

Planned enrollment
94th of 173
230 · median 290
Started
2026
with 7 others
Phase 2/3
6 of 186
4 open now
Primary completion
2031-01
later than 62 of 66 live
Registered
177th of 186
by date
Lead sponsor
8 of 186
Swiss Cancer Institute

Among the 186 studies in Carcinoma, Non-Small-Cell Lung with a site in Switzerland, this one is the 94th largest by planned enrollment of the 173 interventional ones that give a count, is one of 8 that started in 2026, is one of 6 in phase 2/3, reaches primary completion later than 62 of the 66 other live ones, and was the 177th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

42 of the 186 studies in Carcinoma, Non-Small-Cell Lung with a site in Switzerland are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Carcinoma, Non-Small-Cell Lung with a site in Switzerland, or all of them as a file.
02

Study summary

This study investigates whether adding magnesium to the standard chemo-immunotherapy for advanced non-small cell lung cancer (NSCLC) can improve treatment outcomes. Magnesium is important for immune function, and low levels during chemotherapy are common. Participants are randomly assigned to receive either magnesium or a placebo, both as infusions and tablets. Neither the participants nor the doctors know who receives which treatment. The study compares the two groups to see if magnesium helps and how well it is tolerated.

Read the detailed description

This randomized, double-blind, placebo-controlled, multicenter phase II/III trial evaluates the efficacy and safety of intravenous and oral magnesium supplementation in addition to standard first-line chemo-immunotherapy in patients with unresectable stage III or metastatic stage IV non-small cell lung cancer (NSCLC).

Platinum-based chemotherapy frequently induces hypomagnesemia, which may impair T-cell mediated anti-tumor immunity and reduce the effectiveness of immune checkpoint inhibitors. This trial investigates whether correcting magnesium deficiency can enhance immune response and improve clinical outcomes.

The primary objective of the phase II portion is to assess the safety and feasibility of magnesium supplementation and its impact on PFS. If interim analysis confirms tolerability without significant additional toxicity, the trial will seamlessly expand into a phase III component with overall survival (OS) as the primary endpoint.

Secondary objectives include objective response rate (ORR), duration of response (DoR), adverse events (AEs) and serious adverse events (SAEs), health-related quality of life (HRQoL), immune-related biomarkers and magnesium levels.

Patients are randomized to receive either:

  • Magnesium Arm: Standard chemo-immunotherapy + oral magnesium aspartate hydrochloride (3x/day) + intravenous magnesium sulfate on chemo days
  • Placebo Arm: Standard chemo-immunotherapy + matching placebo Magnesium levels are centrally monitored via plasma and urine samples. Anti-cancer therapy follows standard of care.

    230 patients will be enrolled (70 in phase II, 160 in phase III). Eligible patients have stage IIIB/IV NSCLC, ECOG 0-1, and are scheduled for first-line chemo-immunotherapy. Key exclusions include eligibility for monotherapy, severe hypomagnesemia, or ongoing magnesium supplementation for other indications.

Statistical and Quality Considerations

The adaptive design includes an interim analysis for safety and a futility analysis for OS. Time-to-event and binary outcomes will be analyzed using standard statistical methods. Quality assurance includes eCRFs with validation checks, source data verification, SOPs, and risk-based monitoring.

Although not formally a registry, the trial employs registry-like quality control elements:

  • Data validation: Real-time data entry into electronic case report forms (eCRFs) with predefined logic and range checks.
  • Source Data Verification (SDV): Conducted to ensure data accuracy and completeness via comparison with medical records and source documents.
  • Standard Operating Procedures: SOPs are implemented, which cover all trial operations-site initiation, data collection, patient assessments, safety reporting, and amendment handling.
  • Monitoring and auditing: Central and on-site monitoring according to a risk-based monitoring plan. Sites may be audited for compliance with ICH-GCP.

This trial addresses a novel and biologically plausible mechanism of resistance to immunotherapy in NSCLC. By targeting chemotherapy-induced hypomagnesemia, the study explores a low-cost, scalable intervention with the potential to enhance immune-mediated tumor control. If successful, magnesium supplementation could represent a paradigm shift in the supportive care of patients receiving chemo-immunotherapy for advanced NSCLC.

03

Conditions studied

  • Metastatic NSCLC - Non-Small Cell Lung Cancer

Keywords

  • Magnesium supplementation
  • Magnesium aspartate hydrochloride
  • Placebo
  • Non-Small Cell Lung Cancer
  • phase II/phase III
  • unresectable stage III NSCLC
  • metastatic stage IV NSCLC
  • double-blind randomized
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written according to Swiss law and ICH GCP E6 regulations before registration and prior to any trial specific procedures;
  • or cytologically confirmed diagnosis of NSCLC (adeno-, squamous-, large cell carcinoma or NSCLC not otherwise specified);
  • Patients planned for systemic therapy with a combination of a carboplatin-based doublet chemotherapy and a / PD-L1 targeting immune checkpoint inhibitor;
  • Patients not eligible for immune checkpoint inhibitor monotherapy irrespective of PD-L1 expression;
  • Locally advanced unresectable stage III or stage IV disease (defined as TNM, according to 8th edition) not eligible for curative surgery and/or definitive (curative intended) chemoradiotherapy;
  • No sensitizing EGFR mutation, METex14 skipping mutation, BRAF V600E mutation, ALK/ROS1/RET, NTRK1/2 gene rearrangements, mutations, amplifications detected in primary tumor or metastases;
  • Have not received prior systemic treatment for their metastatic NSCLC. Patients who received adjuvant, chemotherapy or chemoradiotherapy with curative intent for nonmetastatic disease are eligible if the therapy was completed at least 12 months prior to the diagnosis of metastatic disease;
  • Patients with treated and stable are eligible, provided they meet the following criteria:

    • No ongoing requirement for as therapy for CNS disease; anticonvulsants at a stable dose allowed
    • No stereotactic radiation or whole-brain radiation within 14 days prior to registration.
  • Patients with known -infection, who are at low risk of AIDS-related outcomes, are eligible, provided they meet the following criteria:

    • are ≥ 350 cells/ųL
    • No history of AIDS-defining opportunistic infection within past 12 months
    • Patients have been on antiretroviral therapy (ART) for > 4 weeks before registration and have a HIV viral load \< 400 copies/mL;
  • Patients with a prior and treated with curative intention are eligible if the treatment of that malignancy was completed at least 2 years before registration and the patient has no evidence of disease at registration. Less than 2 years is acceptable for malignancies with low risk of recurrence and/or no late recurrence;
  • per v1.134);
  • Age ≥ 18 years;
  • (ECOG) performance status 0-1;
  • Adequate bone marrow function as per local guidelines;
  • Adequate hepatic function: total ≤ 1.5 x (except for patients with Gilbert's disease ≤ 3.0 x ULN), and ALT ≤ 2.5 x ULN, or ≤ 5 x ULN under the assumption that abnormal values are a result of NSCLC;
  • Adequate renal function defined by stable estimated (eGFR) ≥ 45 mL/min/1.73 m2 (according to CKD-EPI formula);
  • Women of must use highly effective (see chapter 9.4), are not pregnant or lactating and agree not to become pregnant during trial treatment and until 6 months after the last dose of drug. A negative pregnancy test before inclusion into the trial is required for all women of childbearing potential.
  • Men agree not to donate sperm or to father a child during trial treatment and until 6 months after the last dose of investigational drug.

Exclusion criteria

Exclusion Criteria:

  • Plasma magnesium concentration \< 0.4 mmol/l or > 1.2 mmol/L
  • Treatment with any anti-cancer therapy within 21 days prior to registration (excluding hormonal therapy or anti-cancer surgery). Any previous anti-cancer therapy must have been administered with curative intent;
  • Treatment with radiotherapy within 14 days prior to registration (except for local pain control);
  • Patients planned for cisplatin-based chemo-immunotherapy;
  • Treatment with any other experimental drug within 28 days of registration;
  • Severe or uncontrolled cardiovascular disease (congestive heart failure III or IV), unstable angina pectoris, history of myocardial infarction within the last six months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia);
  • Atrioventricular (AV) block of any degree unless being treated with cardiac pacemakers;
  • Bradycardia \<40/min at steady state;
  • Active chronic or infection or any uncontrolled active systemic infection, needing antibiotic treatment within 14 days before registration;
  • Known history of tuberculosis, known history of relevant primary immunodeficiency, known history of allogeneic organ transplant, receipt of within 28 days prior to registration;
  • Diagnosis of myasthenia gravis;
  • Concomitant or prior use of medication within 28 days before registration, with the exceptions of:

    • intranasal and inhaled
    • systemic corticosteroids ≤ 10 mg/day of prednisone, or a dose equivalent corticosteroid,
    • premedication for chemotherapy;
  • Prior treatment with peroral or intravenous magnesium 14 days prior to registration;
  • Patient not willing to stop the use of peroral magnesium treatment including over the counter or lifestyle products;
  • Any concomitant drugs for use with the trial drug according to the approved product information;
  • Known to any of the trial drugs;
  • Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    Magnesium

    Platinum-based chemo-immunotherapy every 3 weeks \+ Magnesium * intravenous at day 1 of each therapy cycle * peroral thrice daily (day 1-21)

    Drug: Magnesiocard · Drug: Magnesium Diasporal

  • Active comparator
    Placebo

    Platinum-based chemo-immunotherapy every 3 weeks \+ Placebo * intravenous at day 1 of each therapy cycle * peroral thrice daily (day 1-21)

    Other: Microcrystalline cellulose · Other: Isotonic saline solution 0.9%

Interventions

  • DrugAspartic AcidStudies of Aspartic AcidAspartic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    2.5 mmol film-coated tablets in addition to standard first line therapy

  • DrugMagnesium Diasporal

    4 mmol IV formulation in addition to standard first line therapy

  • OtherMicrocrystalline cellulose

    Placebo film-coated tablets corresponding to Magnesiocard in addition to standard first line therapy

  • OtherIsotonic saline solution 0.9%

    Placebo for injection corresponding to Magnesium Diasporal in addition to standard first line therapy

06

What researchers measure

Primary outcomes

  1. Primary endpoint of Phase II part: Progression-free survival (PFS)

    PFS defined as time from randomization to progression according to RECIST 1.1 criteria or death. Patients not experiencing an event will be censored at the date of the last available assessment before initiation of a new anti-cancer treatment, if any.

    Time frame: From randomization to PD or death, up to 10 years

  2. Primary endpoint of Phase III part: Overall survival (OS)

    OS defined as the time from randomization until death due to any cause. Patients not experiencing an event will be censored at the last date they were known to be alive.

    Time frame: From randomization to PD or death, up to 10 years

Secondary outcomes

  1. Toxicity - Intermediate endpoint for the adaptive decision to expand, or not, into a Phase III

    Immune related adverse events (irAEs) ≥ Grade 3 according to NCI CTCAE v5.0

    Time frame: All adverse events: from baseline until end of treatment, deaths: until end of follow-up, up to 10 years

  2. Number of participants discontinued any treatment component.

    Tolerability - Intermediate endpoint for the adaptive decision to expand, or not, into a Phase III. Discontinuation of any treatment component (chemotherapy and/or immunotherapy) within the first 4 cycles of treatment

    Time frame: from baseline until end of treatment, deaths: until end of follow-up, up to 10 years

  3. Event-free survival (EFS)

    EFS is defined as time from registration to one of the following events, whichever occurs first: * Relapse or progression according to RECIST 1.1 criteria * Second tumor * Death due to any cause Patients not experiencing an event will be censored at the date of the last available assessment before initiation of a new anti-cancer treatment, if any.

    Time frame: From randomization to PD, 2nd tumor or death, up to 10 years

07

Study locations

9 of 9 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jan 2031, 51 months after the start.

Of 56 phase 2/3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40. This study's planned 51 months is close to that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Sep 2, 2025
StartActual
Sep 29, 2026was Aug 2026
Primary completionEst.
Jan 1, 2031
CompletionEst.
Mar 31, 2035
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 3 sites removed
Show site
  • HOCH Health Ostschweiz - Kantonsspital St. Gallen · Sankt Gallen, Switzerland
Show 3 removed
  • Kantonsspital Aarau · Aarau, Switzerland
  • Kantonsspital - St. Gallen · Sankt Gallen, Switzerland
  • Spital STS AG · Thun, Switzerland
Oct 28, 2026
Start date
Aug 2026→Sep 29, 2026 (actual)
Oct 23, 2026
Show all 2 updates
  1. Oct 28, 2026
    1 site added, 3 sites removed
    Show site
    • HOCH Health Ostschweiz - Kantonsspital St. Gallen · Sankt Gallen, Switzerland
    Show 3 removed
    • Kantonsspital Aarau · Aarau, Switzerland
    • Kantonsspital - St. Gallen · Sankt Gallen, Switzerland
    • Spital STS AG · Thun, Switzerland
  2. Oct 23, 2026
    Start date Aug 2026→Sep 29, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07149649
Lead sponsor
Swiss Cancer Institute
Responsible party
Sponsor
First posted
Sep 2, 2025
Start date
Sep 29, 2026
Primary completion
Jan 1, 2031 (estimated)
Completion
Mar 31, 2035 (estimated)
Last update
Oct 28, 2026

Study contacts

Gisela Müller, PhD
Contact
trials@swisscancerinstitute.ch
+41 31 389 91 91
Jonas Lötscher, MD, PhD
study chair · CH - Universitätsspital Basel
Sacha Rothschild, Prof MD, PhD
study director · CH - Kantonsspital Baden
Christoph Hess, Prof MD, PhD
study director · CH - Universitätsspital Basel

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspartic Acid

Start the discussion